CF:RVV Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers novel cannabinoid-centric treatments for liver diseases, inflammatory diseases, and skin disorders. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and coronavirus disease; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocybin oral formulations for the treatment of depression, anxiety, etc.; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has a research collaboration agreement with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; and with North Carolina State University for the development of a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol RVVTF.

This company has cross-listed shares that trade in the U.S. as the symbol RVVTF.

0.36 CAD
As of 09/27/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Canadian Securities Excha
Exchange country:   Canada
Market cap:   116,657,288 CAD
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy